Trial Profile

An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jan 2018 Results assessing efficacy and tolerability of a continuous delivery subcutaneous formulation of exenatide in patients with type 2 diabetes mellitus that is inadequately controlled with diet and exercise alone or in combination with oral antihyperglycaemics with high baseline HbA1c, were published in the Diabetes Care.
19 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
16 Sep 2016 Results of procedure experience from this and other three trials of FREEDOM Phase 3 program (n=5200) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com